Atea Pharmaceuticals, Inc.

AI-generated fair value estimate for this company.

Method: Risk-adjusted NPV (rNPV) of the lead HCV program (bemnifosbuvir plus ruzasvir, Phase 3 primary endpoints already met; company-guided ~$700M peak sales) plus net cash: near-term cash burn of -$100M (year 1) and -$50M (year 2) unweighted; post-launch FCF at a 30% margin on peak sales ramped 25%/55%/80% of peak in years 3-5 and held at 100% in years 6-10; post-approval cash flows risk-weighted at an 80% probability of success; 12% discount rate; no terminal value added beyond year 10. PV of risk-adjusted program cash flows ~$379M; plus reported cash of $219.5M (Q2 2026) gives equity value ~$599M; divided by 80.2M diluted shares gives ~$7.47/share.

Reasoning: Atea is a clinical-stage, pre-revenue biopharma, so an operating-FCF DCF is not meaningful; rNPV built around its most advanced, largely de-risked asset (positive Phase 3 readout) plus net cash is the standard rigorous method for a single-asset biotech at this stage.